From seed to market, Landos finds a partner in Perceptive

LianBio will provide newly public autoimmune company Landos with a bridge to Asia for its two most advanced programs, as the cross-border company adds its seventh and eighth assets to its portfolio and enters a fifth disease category.

Announced Monday, the partnership is at least the fourth deal for Landos Biopharma Inc. (NASDAQ:LABP) with a Perceptive Advisors vehicle and illustrates how the New York City-based investment firm has begun to build a one-stop shop to carry a company from seed to IPO and eventually onto the market in China...